Drug Trial Radar · NCT04322890
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6,000
Planned (sponsor's estimate)
Start
Apr 16, 2020
Primary completion
Dec 24, 2026
Study completion Dec 24, 2027
Sponsor
- Lead sponsor
- Hunan Province Tumor HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
Conditions
- Non Small Cell Lung Cancer
- EGFR Gene Mutation
- ALK Gene Mutation
- ROS1 Gene Mutation
- MET Gene Mutation
Interventions
OsimertinibDrug
Osimertinib 80mg, po, qd;
Alectinib 150 MGDrug
Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;
Crizotinib 250 MGDrug
Crizotinib 250 MG po bid.
Savolitinib, Crizotinib.Drug
Savolitinib, 300mg po qd.
ChemotherapyDrug
500mg, ivgtt, every 21day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Time from first subject dose to study completion, or up to 36 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yongchang Zhang
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.